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Abstract 
The shugoshin 1(sgo 1) belongs to the family of mitotic kinase and plays an important role in 
mitosis. For example, sgo 1 is involved in maintenance of centromeric cohesion from prophase to the 
metaphase-anaphase transition, regulating kinetochore microtubule stability, sensing interkinetochore 
tension and ensuring bipolar attachment of kinetochores. Aberrant expression of the mitotic kinase is 
associated with chromosomal instability, a common feature of hematological malignancies. The 
present study found that sgo 1 was aberrantly expressed in a variety of types of human leukemia cell 
lines (n=10, e.g., HL-60,NB4, MOLM-13,K562,EOL-1, etc.), as well as freshly isolated leukemia 
cells from individuals with acute myelogenous leukemia(AML, n=43) compared with bone marrow 
mononuclear cells from healthy volunteers (n=9), as measured by real-time PCR. In addition, we 
found that depletion of sgo 1 by a small interfering RNA (siRNA) slowed the proliferation of NB-4 
and EOL-1 cells compared to the control siRNA transfected cells, in parallel with induction of 
precocious dissociation of centromeric cohesion and separation of sister chromatids in these cells. 
Furthermore, we found that sgo 1 silencing by siRNA accumulated EOL-1 cells in the M phase of 
the cell cycle, followed by apoptosis, as measured by cell cycle analysis and detection of the cleaved 
forms of caspase 3 and PARP by immunocytochemistry, respectively. Taken together, sgo 1 may be a 
promising molecular target for individuals with AML. 
 
 
 
 
 
 
 
 
